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to be performed. I consider that the connection between the outcomes and the double objective set should be considered and clarified. On the other hand, it is uncertain how the objective of estimating the impact or effect of the interventions is going to be measured by means of the outcomes described. Methodology always should respond to the objectives of the work, so its clear relation is all-important. The sentence in page 10 line 19 should be clarified. What does "depending on the resources available" mean? In the "Types of studies "section, you should add that antibiotic prescribing considered will be referred to RTIs. The first priority you will give to studies in English must be clarified; it is not well explained in the Study selection. Will you not include any term describing the effect, impact or outcome among the search strategies? You should consider it. The sentence in page 12 line 12 is not clear. What does "as required" mean? In "Data extraction and management" section, the point f) is confusing. How is the "the value of appropriateness and/or inappropriateness of antibiotic prescribing that has been adjudicated to an outcome by the study reviewers" going to be measured? The explanation is vague and inadequate. Who are the study reviewers? What is their background? Which resources are they going to use to estimate appropriateness? If it consists on a subjective assessment, then the quality indicators and measures used should be based on previous studies. Explain more in detail this point. In the "Risk of bias assessment", page 14 line 26, you should describe in which way are these criteria going to be used to decide about the quality of studies. Data analysis: I do not understand why you are planning the calculation of both p-values and confidence intervals. Studies with high risk of bias, dubious criteria for inclusion, etc. should be considered not only for excluding studies from the sensitivity analysis, but also from the review. I consider it is preferable if their quality is not appropriate. Discussion: it is correct and clear. The sentence page 16 line 17 should be better explained ("impact and assessment of their interaction", what does it mean?). Limitations and strengths should be included here.
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Reviewer: 1 Reviewer Name: Sara Malo Institution and Country: University of Zaragoza, Spain Competing Interests: None declared Interesting proposal to increase evidence about the effectiveness of interventions addressed to minimize a worldwide public health problem. It consists of a well-designed protocol, appropriate for achieving the objective set, but with several aspects that must be clarified and better specified and are explained below.
1. First of all, I recommend the manuscript is reviewed by a native English speaker, since some sentences and ideas can be better explained. Authors" response: We revised and improved the text. Two native English speakers proofread the manuscript.
2. Abstract: it does not describe entirely the objective of the systematic review. The Methodology should also be better described and organized, using the same writing style and verb tense along the whole section. As described below, the definition of both primary and secondary outcomes is not completely clear. Authors" response: Thank you for this comment. We revised and improved the abstract, refined the objective(s) of the review and re-organised the methodology, explicitly stating the primary and secondary outcomes in the abstract; please see Page 2.
3. The "Strengths and limitations of this study" section should be merged with the rest of Discussion, and be written as a text, not a list. Authors" response: Thank you for this comment. Including a strengths and limitations section after the abstract is a journal requirement. The Editorial team has recommended not to revise this section.
4. Introduction: it presents comprehensibly the extent of AMR, its causes, factors related to antibiotic use and misuse, and interventions. However, the manner of presenting the hypothesis, the objectives and review questions results confusing. It is assumed that all of them should be related, but it is difficult to find the connection between the two objectives; the terms effectiveness, feasibility and acceptability; and the primary and secondary outcomes later described. Authors" response: Thank you for this comment. We have revised the section and made the following changes: a) The text for objectives and hypothesis and their relation to the terms effectiveness, feasibility and acceptability has changed as follows (Page 6, line 11): "This systematic review will appraise the existing evidence and estimate the effectiveness of interventions aiming to improve the quality of antibiotic prescribing and use for acute RTI in primary care. Our second objective is to assess the feasibility and acceptability of patient-and cliniciantargeted interventions. We also expect to identify the intervention components that are most strongly associated with effectiveness. We hypothesise that interventions aimed at improving the quality of antibiotic prescribing and use for RTIs: 1) are more effective in reducing inappropriate antibiotic prescribing, dispensing by healthcare professionals (clinicians and/or pharmacists), and use by patients, their carers or parents when multiple components are integrated to target both patients and healthcare professionals; and 2) work better at reducing antibiotic use-related problems when they target healthcare professionals and patients by means of public campaigns. We also hypothesise that such interventions are even more effective in making a step-change when they are implemented at the system-level by means of regulatory measures. In addition, knowing the feasibility and acceptability of patient-and cliniciantargeted interventions may help explain their comparative effectiveness and guide their implementation in practice."
b) For clarity, we moved the review questions to the Methods section (Page 7, line 9).
c) We have re-organised the outcomes section and added the subheadings "Effectiveness" and "Feasibility and acceptability" to split the outcomes so that they clearer relate to the objectives of the review. Please see authors" response to comment no. 7 and manuscript Page 9, line 10. 6. The "types of interventions comparators" should be included in the "Types of intervention" section, explaining the differences between them. Authors" response: Thank you for this comment. We have revised the section and included the intervention comparators under the section "Types of intervention" as follows (Page 8, line 26): "Types of interventions and comparators… Comparators will include alternative interventions that also aim to improve antibiotic prescribing and use for RTIs including interventions consisting of one or multiple components, or usual care."
7. The "types of outcome measures" section is confusing and complicated to understand, since it is not clear how the measurement of effectiveness, feasibility and acceptability is going to be performed. I consider that the connection between the outcomes and the double objective set should be considered and clarified. On the other hand, it is uncertain how the objective of estimating the impact or effect of the interventions is going to be measured by means of the outcomes described. Methodology always should respond to the objectives of the work, so its clear relation is all-important. Authors" response: Thank you for this comment. We have re-organised the objectives, review questions and outcomes sections to make their relation clearer. The review questions on "Effectiveness" and "Feasibility and Acceptability" are now stated on page 7; and how these will be measured in terms of outcomes is explained later in the manuscript under section "Types of outcome measures" (Page 9, line 10). We split the outcomes into EFFECTIVENESS, and FEASIBILITY AND ACCEPTABILITY as follows (Page 9, line 19 to page 11, line 3): "Types of outcome measures We will extract primary and secondary outcomes to measure the effectiveness, feasibility and acceptability of interventions, regardless of the outcome measurement instruments used, the outcome measure (e.g. prescribed individuals, prescriptions, items as numerators, and RTI patients or patient years "at risk" as denominators), [43] [44] [45] their nature (objective or subjective) and time points.
EFFECTIVENESS Primary outcomes
For all interventions to improve antibiotic use, the effect of interventions on the quality of antibiotic prescribing and use will be measured by means of:
• rates and types of (any) antibiotics prescribed and/or used for primary care patients with acute RTI • rates and types of guideline-recommended antibiotics prescribed for primary care patients with acute RTI Secondary outcomes For healthcare professional and patient-targeted interventions, the effect of interventions on the quality of antibiotic prescribing and use will be measured by means of:
• rates and types of antibiotics prescribed as immediate and delayed use FEASIBILITY AND ACCEPTABILITY Secondary outcomes For patient-and clinician-targeted interventions, the feasibility and acceptability of interventions to improve the quality of antibiotic prescribing and use measured as, for example, satisfaction with the intervention or uptake of interventions."
8. The sentence in page 10 line 19 should be clarified. What does "depending on the resources available" mean? Authors" response: Thank you for this comment. Given the comprehensiveness of our systematic review, the amount of work necessary to extend the extraction of secondary outcomes for studies of campaigns and regulatory interventions might require more reviewers than currently available in our team. Processing these data, however, might not represent a huge extra effort once we know the number of eligible studies. We have revised this section as follows (Page 10, line 19): "Depending on the number of reviewers available in our team, we may also assess the secondary outcomes for studies of campaigns and regulatory interventions (e.g. antibiotic resistance, types and rates of medical complications, the costs of healthcare services, programs and (dispensing) medication, and healthcare utilisation)."
9. In the "Types of studies "section, you should add that antibiotic prescribing considered will be referred to RTIs. Authors" response: Thank you for this comment. We have revised this section and we refer to RTIs as recommended (Page 11, lines 6-20): "For healthcare professional (clinicians and/or pharmacists) and patient-targeted interventions, we will include …: a) evaluate the effectiveness of interventions to improve antibiotic prescribing and/or use for RTIs; and/or b) evaluate the feasibility and acceptability of patient and clinician-targeted "interventions to improve antibiotic use for RTIs in primary care general practice "For public awareness (local, national, and "choosing wisely") campaigns[39-40] …: a) evaluate the effectiveness of interventions to improve antibiotic prescribing and/or use for RTIs"
10. The first priority you will give to studies in English must be clarified; it is not well explained in the Study selection. Authors" response: Thank you for this comment. Given the comprehensiveness of our systematic review, the amount of work necessary to extend the extraction of secondary outcomes for studies of campaigns and regulatory interventions might require more reviewers than currently available in our team. Processing these data, however, might not represent a huge extra effort once we know the number of eligible studies. We have revised the sections "Type of studies" and "Study selection" and clarified as follows (Page 11, line 22): "Types of studies… "We aim to include studies published in English and other languages. We will give priority to the inclusion of studies published in English. Depending on the number of reviewers available in our team, we will include studies published in languages other than English in the following order: Spanish, German and other languages (see study selection)."
Please also see Page 13, line 3): "Study selection…" "We will prioritise the selection of studies published in English. Depending on the number of reviewers available in our team, we will also appraise the citations and publications of studies published in languages other than English in the following order: Spanish, German and other languages."
11. Will you not include any term describing the effect, impact or outcome among the search strategies? You should consider it. Authors" response: We aim to assess the effectiveness as well as the feasibility and acceptability of the interventions of interest. We therefore decided to perform a search strategy broad enough to identify the studies that provide us with such evidence. By adding the terms "effect" or "outcome" we could be restricting the search more to the identification of studies with these terms.
12. The sentence in page 12 line 12 is not clear. What does "as required" mean? Authors" response: Thank you for this comment. We have revised the section and clarified as follows (Page 12, line 27): "We might update the searches of relevant databases before publication of the review to screen for further potentially eligible studies."
13. In "Data extraction and management" section, the point f) is confusing. How is the "the value of appropriateness and/or inappropriateness of antibiotic prescribing that has been adjudicated to an outcome by the study reviewers" going to be measured? The explanation is vague and inadequate. Who are the study reviewers? What is their background? Which resources are they going to use to estimate appropriateness? If it consists on a subjective assessment, then the quality indicators and measures used should be based on previous studies. Explain more in detail this point. Authors" response: Thank you for this comment. We have revised the section and have corrected a mistake (Page 14, line 14). We mean "study authors" (of eligible studies in our review) and not "study reviewers". We will extract the value of appropriateness and/or inappropriateness as follows: "f) outcome details: the value of "appropriateness" and/or "inappropriateness" that authors of eligible studies have adjudicated to antibiotics prescribing and/or use;" 14. In the "Risk of bias assessment", page 14 line 26, you should describe in which way are these criteria going to be used to decide about the quality of studies. Authors" response: Thank you for this comment. We have revised this section, added "the necessary explanation" and readapted the relevant sentences as follows (Page 15, line 5): "The validity of eligible studies will be determined by rating the adequacy of each core item. RCTs of adequate quality will be those with an adequate generation of random sequence, concealment of allocation (at randomisation), and blinding of outcome assessors based on established guidelines [47] . Bias due to attrition will be considered as being of significant concern if there is a loss to followup of at least 20%; ITT will be considered adequate if authors analysed participants based on their original group allocation."
15. Data analysis: I do not understand why you are planning the calculation of both p-values and confidence intervals. Authors" response: Thank you for this comment. BMJ Open requires that the results for quantitative studies "include the 95% confidence intervals and, where appropriate, the exact p-values". Further, for the interpretation of results, some prefer the presentation of p-values to confidence intervals. However, the presentation of both CIs and p-values could provide readers with a better understanding of the results and avoid misinterpretations; for example, the meaning of a p-value of > 0.05 might be treated as "no effect", which might more correctly mean "not strong evidence of an effect". We revised this section follows (Page 15, line 25): "Where sufficient detail allows their calculation, the summary statistics and 95% CIs together with the exact p-values will be reported."
16. Studies with high risk of bias, dubious criteria for inclusion, etc. should be considered not only for excluding studies from the sensitivity analysis, but also from the review. I consider it is preferable if their quality is not appropriate. Authors" response: Thank you for this comment. We agree that excluding from the review the studies with higher risk of bias is one approach to handle the evidence in regards to quality. The assessment of risk of bias is subjective by nature. We prefer to initially include all studies regardless of their risk of bias, but to remove from the analyses the studies with higher risk of bias. This would allow us to present all results transparently while observing how much the results are affected by variation in their quality, if at all.
17. Discussion: it is correct and clear. The sentence page 16 line 17 should be better explained ("impact and assessment of their interaction", what does it mean?). Limitations and strengths should be included here. Authors" response: Thank you for this comment. We have revised and corrected as follows (Page 17, line 4): "The evaluation of these interventions will allow a comparison of their impact, providing unique information to policy makers."
Including a strengths and limitations section after the abstract is a journal requirement. The Editorial team has recommended not to revise this section.
